title: Helicobacter pylori as a class I carcinogen: physiopathology and management strategies.
abstract: The gram-negative bacterium Helicobacter pylori is known as a persistent colonizer of the human stomach, and probably less known is that it is also involved in extraintestinal diseases. Public awareness of its contribution in the development of gastric cancer is less than 15 years old. The efficacy of the current therapies based on antibiotics against H. pylori has been limited by difficulties such as antibiotic resistance and recurrence. As a consequence, the development of promising vaccines was prompted as the best preventive measure. Unfortunately, so far vaccines failed the transition from animal models to human trials. This keynote presentation is to provide a bird's eye view of H. pylori-related gastric diseases, including gastric cancer, with a synthesis of the molecular mechanisms involved, and an exhaustive presentation and discussion of the current therapeutic guidelines and future strategies for prevention or therapy.
authors.affiliation: Sbarro Institute for Cancer Research and Molecular Medicine, Centre for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122, USA.
authors.forename: Paraskevi
authors.initials: P
authors.lastname: Vogiatzi
authors.forename: Marco
authors.initials: M
authors.lastname: Cassone
authors.forename: Ida
authors.initials: I
authors.lastname: Luzzi
authors.forename: Chiara
authors.initials: C
authors.lastname: Lucchetti
authors.forename: Laszlo
authors.initials: L
authors.lastname: Otvos
authors.forename: Antonio
authors.initials: A
authors.lastname: Giordano
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001428:Bacterial Vaccines; D019496:Cancer Vaccines / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D005756:Gastritis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000382:microbiology* / Q000517:prevention & control; D016480:Helicobacter pylori / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000382:microbiology* / Q000517:prevention & control; D010437:Peptic Ulcer / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000382:microbiology* / Q000517:prevention & control
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D001428:Bacterial Vaccines; D019496:Cancer Vaccines